1. ATLAS OF PET-CT, A Quick Guide to Image Interpretation

   • Ignasi Carrió

   Book Review 05 December 2019 Pages: 515 - 516

2. Radiology and nuclear medicine: advancing together in the era of precision medicine

   • Arturo Chiti
   • Yves Menu

   Editorial 15 January 2020 Pages: 517 - 518

3. Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies

   • Frederik A. Verburg
   • Martha Hoffmann
   • Markus Luster

   Editorial 05 December 2019 Pages: 519 - 522

4. ¹⁸F-FDG PET/CT in patients with post-transplant lymphoproliferative disorders: so far so good

   • Giorgio Treglia
   • Luca Ceriani

   Editorial 04 September 2019 Pages: 523 - 524

5. Letter to the Editor: ¹⁸F-NaF not cited in the EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma

   • Paulo Schiavom Duarte

   Letter to the Editor 18 November 2019 Pages: 525 - 526

6. ¹⁸F-Fluoride (¹⁸F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines!

   • Giorgio Treglia
   • Luca Giovanella

   Letter to the Editor 21 November 2019 Pages: 527 - 528

7. Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield

   • F. M. Montes de Jesus
   • T. C. Kwee
   • W. Noordzij

   Original Article Open access 24 August 2019 Pages: 529 - 536

   

8. Chemokine receptor-4 targeted PET/CT with ⁶⁸Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to ¹⁸F-FDG PET/CT

   • Qingqing Pan
   • Xinxin Cao
   • Fang Li

   Original Article 27 November 2019 Pages: 537 - 546

   

9. Assessment of the impact of 2015 American Thyroid Association guidelines in management of differentiated thyroid cancer patients

   • Sayak Choudhury
   • Archi Agrawal
   • Venkatesh Rangarajan

   Original Article 09 November 2019 Pages: 547 - 553

   

10. Variations in radioiodine ablation: decision-making after total thyroidectomy

    • O. Maas
    • F. Forrer
    • P. M. Putora

    Original Article 09 November 2019 Pages: 554 - 560

    

11. Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study

    • Seong Young Kwon
    • Sang-Woo Lee
    • Korean Society of Nuclear Medicine (KSNM) Thyroid Cancer Clinical Trial Network (CTN) Retrospective Cohort Study Group

    Original Article 10 December 2019 Pages: 561 - 571

    

12. Superior performance of 18F-fluorocholine digital PET/CT in the detection of parathyroid adenomas

    • Diego Alfonso López-Mora
    • Marina Sizova
    • Ignasi Carrió

    Original Article 09 January 2020 Pages: 572 - 578

    

13. [¹⁸F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0

    • Cristina Nanni
    • Lucia Zanoni
    • David M. Schuster

    Guidelines 11 December 2019 Pages: 579 - 591

    

14. ¹⁸F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer

    • Christos Sachpekidis
    • A. Afshar-Oromieh
    • A. Dimitrakopoulou-Strauss

    Original Article 14 November 2019 Pages: 592 - 602

    

15. Deep neural network for automatic characterization of lesions on ⁶⁸Ga-PSMA-11 PET/CT

    • Yu Zhao
    • Andrei Gafita
    • Kuangyu Shi

    Original Article 07 December 2019 Pages: 603 - 613

    

16. Digital versus analogue PET in [⁶⁸Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison

    • Ian Alberts
    • George Prenosil
    • Ali Afshar-Oromieh

    Original Article 02 December 2019 Pages: 614 - 623

    

17. ⁶⁸Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol

    • Fabian Haupt
    • Lotte Dijkstra
    • Ali Afshar-Oromieh

    Original Article 01 November 2019 Pages: 624 - 631

    

18. The effect of androgen deprivation therapy on ⁶⁸Ga-PSMA tracer uptake in non-metastatic prostate cancer patients

    • Cem Onal
    • Ozan Cem Guler
    • Ali Fuat Yapar

    Original Article 15 November 2019 Pages: 632 - 641

    

19. The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia

    • Ian Alberts
    • Christos Sachpekidis
    • Ali Afshar-Oromieh

    Original Article 21 December 2019 Pages: 642 - 651

    

20. Impact of ⁶⁸Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer

    • Daniela A. Ferraro
    • Helena I. Garcia Schüler
    • Irene A. Burger

    Original Article 04 December 2019 Pages: 652 - 664

    

21. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with ⁶⁸Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer

    • Otto Ettala
    • Simona Malaspina
    • Jukka Kemppainen

    Original Article Open access 26 December 2019 Pages: 665 - 673

    

22. The management impact of ⁶⁸gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (⁶⁸Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer

    • Meghana Kulkarni
    • Simon Hughes
    • Gary J. R. Cook

    Original Article Open access 23 December 2019 Pages: 674 - 686

    

23. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide

    • Florian Rosar
    • Sebastian Dewes
    • Samer Ezziddin

    Short Communication 03 January 2020 Pages: 687 - 694

    

24. The ⁶⁸Ga/¹⁷⁷Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

    • Johanna Maffey-Steffan
    • Lorenza Scarpa
    • Irene Virgolini

    Original Article Open access 27 November 2019 Pages: 695 - 712

    

25. Clinical outcome of standardized ¹⁷⁷Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

    • Sazan Rasul
    • Marcus Hacker
    • Alexander R. Haug

    Original Article Open access 28 November 2019 Pages: 713 - 720

    

26. ²²⁵Ac-PSMA-617/¹⁷⁷Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience

    • Fadi Khreish
    • Niklas Ebert
    • Samer Ezziddin

    Original Article 22 November 2019 Pages: 721 - 728

    

27. Planar scan vs. SPECT/low-dose CT for estimating split renal function by ^99mTc-DMSA scintigraphy in children

    • Michala Holm Reichkendler
    • Ronan M. G. Berg
    • Lise Borgwardt

    Short Communication 15 November 2019 Pages: 729 - 733

    

28. Extranodal involvement of multiple organs in diffuse large B cell lymphoma detected on ¹⁸F-FDG PET/CT

    • Tianbin Song
    • Rong Rong
    • Jie Lu

    Image of the Month 08 January 2020 Pages: 734 - 735

    

29. Isolated involvement of thyroid gland by IgG4-related disease revealed by ¹⁸F-FDG PET/CT

    • Yuanyuan Jiang
    • Guozhu Hou
    • Wuying Cheng

    Image of the Month 25 November 2019 Pages: 736 - 737

    

30. Zirconium-89 labelled rituximab PET-CT imaging of Graves’ orbitopathy

    • Bart de Keizer
    • Kamil G. Laban
    • Rachel Kalmann

    Image of the Month Open access 18 November 2019 Pages: 738 - 739

    

31. Correction to: The ⁶⁸Ga/¹⁷⁷Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

    • Johanna Maffey-Steffan
    • Lorenza Scarpa
    • Irene Virgolini

    Correction 20 December 2019 Pages: 740 - 740